# Consumer Review

Question: **Was the read itself valuable enough for a human or agent to trust, reuse, or act on?**

> Reviewed via the Loop-2 adversarial workflow (consumer pass, Sonnet), cross-checked against
> the evidence-verifier pass.

## Verdict

- **Valuable? Yes.**
- **Why:** It *answered* a decisive comparative question rather than re-confirming a saturated
  one. Run 014 found a clinical backend (OpenLoop) joining 2 GLP-1 brands and asked whether
  that was a GLP-1 artifact; run 016 answers **no, but the axis flips** — outside GLP-1 the
  shared, store-joinable backend is the **pharmacy** (Strive Pharmacy → `strivepharmacy-com`,
  named by hevahealth + invigormedical). That mirror-image structural finding is genuinely
  novel and advances a parked design decision (MRL-005), not a saturated one.
- **What the consumer can do now:** Trigger the human MRL-005 graduation decision (the
  recurrence-test bar is now met on a second cohort + second axis); the minimal shape must
  carry **both** `clinical_provider:` and `pharmacy_partner:` dotted-domain fields. Watch
  future TRT/longevity/peptide captures for a third brand naming Strive (would convert the
  recurrence lead into a defensible concentration claim).
- **What made it safer / better than generic Claude + web search:** Store-only, zero spend,
  every claim traced to local `telehealth.md`/`profile.md` with claim IDs (C1–C11) and one
  derivation receipt. The named-vs-possessive guard (run-001 trap) was applied — no "our
  pharmacy" language counted as an entity. Entity resolution checked actual `store/` contents.
  A web search could not produce this cross-brand backend map: most pharmacy partnerships
  aren't prominently advertised and were only extractable from captured store prose.
- **Biggest limit:** Denominators are floors (anchored-only grep, MRL-001); many brands route
  to an unnamed "partner pharmacy," so the substrate is larger than the named floor. 2-brand
  co-occurrence is a recurrence lead, not measured concentration. Olympia name-variant
  inferred, not adjudicated. All evidence is owned-page self-report.
- **Human follow-up needed:** the MRL-005/006 graduation call (human-gated).

## Value diagnostics

| Signal | Evidence / gap |
|---|---|
| **Useful** | Decisive yes/no + a concrete capture-candidate direction; not a summary. |
| **Judgment-ready** | Rare cross-brand backend map a downstream system could reason from; judgments labeled J1–J3. |
| **Sourced & cited** | C1–C11 → one derivation receipt; one overclaim (belmar "joinable") caught and corrected in Loop 2. |
| **Deep enough** | Covered all 35 anchored non-GLP-1 brands, not exemplars. |
| **Fresh enough** | Store clock 06-04→06-18 surfaced; no current claims made. |
| **Kept / reusable** | Warm receipt + recurrence table make the next relation read cheaper. |

## Job fit

| Job | Did the read help? | Missing / next step |
|---|---|---|
| **Compare a whole field** | Yes — cross-brand backend-dependency map across 5 cohorts. | Resolve dangling compounders to make it joinable at depth. |
| **Build on top without re-capturing** | Yes — labeled State + one joinable edge (Strive) a downstream system could query. | `pharmacy_partner:` field is not yet a primitive (human-gated). |
| **Five-second brief input** | Yes — "DTC brands are skins over a smaller compounder pool; the joinable axis flips GLP-1↔non-GLP-1" lands in one sentence. | — |

## Lens check

- **Strategist:** lands fast — the axis-flip is a one-sentence structural insight.
- **The Pantry / downstream system:** usable as ingredients; Strive edge joins, judgments
  labeled, floors visible. The belmar overclaim would have mildly misled a downstream join
  until corrected.
- **First Contact:** trustworthy — discipline clean (store-only, no spend, no overreach on
  "concentration"), and the one error was caught by the adversarial pass and fixed.

## Triage submissions

Adds new evidence — see `run-notes.md` Triage submissions and the MRL-005/006/001 Evidence
Log appends made in `triage.md`. No graduation.
